Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3 Genetic pleiotropy in ALS

Published byΠρίσκα Ελευθεριάδης Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 3 Genetic pleiotropy in ALS"— Presentation transcript:

1 Figure 3 Genetic pleiotropy in ALS
Figure 3 | Genetic pleiotropy in ALS. Several genetic variants associated with amyotrophic lateral sclerosis (ALS) are also associated with frontotemporal dementia (FTD). In this stalagmite plot, the size of each plotted point is in direct proportion to the number of publications on ALS and FTD that reference the gene specified. The position on the x-axis corresponds to the proportion of publications in ALS and FTD. Al-Chalabi, A. et al. (2016) Gene discovery in amyotrophic lateral sclerosis: implications for clinical management Nat. Rev. Neurol. doi: /nrneurol

Download ppt "Figure 3 Genetic pleiotropy in ALS"

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Three Families With Amyotrophic Lateral Sclerosis.

Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Three Families With Amyotrophic Lateral Sclerosis.
Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi:10/1038/nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Life expectancy at birth in all countries included

Figure 3 Life expectancy at birth in all countries included
MRI and possible differentiating features with nonconventional MRI

MRI and possible differentiating features with nonconventional MRI
Figure 2 The US Centers for Disease Control and

Figure 2 The US Centers for Disease Control and
Figure 4 Time course of the development of physiological changes

Figure 4 Time course of the development of physiological changes
Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 4 Cerebrospinal fluid levels of neurofilament light chain

Figure 4 Cerebrospinal fluid levels of neurofilament light chain
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 2 Overview of risk factors for Parkinson disease dementia

Figure 2 Overview of risk factors for Parkinson disease dementia
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Similar presentations

Ads by Google